REFERENCES
- Aiello LP, George DJ, Cahill MT, Wong JS, Cavallerano J, Hannah AL, Kaelin WG Jr. Rapid and durable recovery of visual function in a patient with von Hippel-Lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416. Ophthalmology. 2002 Sep; 109(9):1745–1751.
- Aumiller MS. Juxtapapillary hemangioma: a case report and review of clinical features and management of von Hippel-Lindau disease. Optometry. 2005 Aug; 76(8):442–449.
- Dahr SS, Cusick M, Rodriguez-Coleman H, Srivastava SK, Thompson DJ, Linehan WM, Ferris FL 3rd, Chew EY. Intravitreal anti-vascular endothelial growth factor therapy with pegaptanib for advanced von Hippel-Lindau disease of the retina. Retina. 2007 Feb; 27(2):150–158.
- Friberg TR. Clinical experience with a binocular indirect ophthalmoscope laser delivery system. Retina. 1987; 7:28–32.
- Girmens JF, Erginay A, Massin P, Scigalla P, Gaudric A, Richard S. Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas. Americal Journal of Ophthalmology. 2003 July; 194–196.
- Palmer JD, Gragoudas ES. Advances in treatment of retinal angiomas. Int Ophthalmol Clin. 1997 Fall; 37(4):159–170.
- Wittebol-Post D, Hes FJ, Lips CJ.The eye in von Hippel-Lindau disease. Long-term follow-up of screening and treatment: recommendations. J Intern Med. 1998 Jun; 243(6):555–561.
- Wittenberg L, Ma P. Treatment of a von Hippel-Lindau retinal capillary hemangioma with photodynamic therapy. Canadian Journal of Ophthalmology. 2008; 43:605–606.
- Wong W, Yeh S, Chan CC, Kalina R, Kinyoun JL, Folk JC, Coleman H, Chew E. Retinal vascular proliferation as an ocular manifestation of von Hippel-Lindau Disease. Arch Ophthalmol. 2008 May; 126:637–643.
- Wong W, Chew E. Ocular von Hippel-Lindau disease: clinical update and emerging treatments. Curr Opin Ophthalmol. 2008; 19:213–217.